GelMEDIX partners with Catalent to advance vision-restoring cell therapies
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
Subscribe To Our Newsletter & Stay Updated